The Journal of Rheumatology

VOLUME 42: NO. 10

Contents continued on page xx

Free online via JRheum Full Release option

Editorials

Gout and Association with Erectile Dysfunction
A.C. Gelber .................................................. 1731

The Renaissance of Antineutrophil Cytoplasmic Antibodies as a Predictor of Relapse: Ippon for Japan
J.W. Cohen Tervaert .................................. 1734

Do “Evidence-Based Recommendations” Need to Reveal the Evidence? Minimal Criteria Supporting an “Evidence Claim”
R. Christensen, J.A. Singh, G.A. Wells, P.S. Tugwell ................................ 1737

Articles

Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with RA
A. Kastbom, L. Årlestad, S. Rantapää-Dahlqvist ................................. 1740

Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with RA

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active RA despite DMARD Therapy
M.C. Genovese, E. Hsia, S.M. Belkowski, et al .................... 1752

Longterm Safety of Rituximab: Final Report of the RA Global Clinical Trial Program over 11 Years
R.F. van Vollenhoven, R.M. Fleischmann, D.E. Furst, S. Lacey, P.B. Lehane .......... 1761


Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician’s Sex: Data on Patients with RA, Axial SpA, and PsA from the DANBIO Registry C. Lindström Egholm, N.S. Krogh, T. Pincus, et al .......... 1781

Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis


Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in SSc
J. Avouac, G. Riemekasten, C. Meune, B. Ruiz, A. Kahan, Y. Almanor ........... 1801

The Endothelial-mesenchymal Transition in SSc is Induced by Endothelin-1 and TGF-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist


Reduction of Inflammation Drives Lipid Changes in Ankylosing Spondylitis


Maternal and Neonatal Outcomes in 89 Patients with Takayasu Arteritis (TA): Comparison Before and After the TA Diagnosis A.L. Assad, T.F. da Silva, E. Bonfa, R.M. Pereira .......... 1861

Comparison of 2 Dosages of Intraarticular Triamcinolone for the Treatment of Knee Arthritis: Results of a 12-week Randomized Controlled Clinical Trial J.W. Popma, F.W. Snel, C.J. Haagsma, et al .......... 1865

Association Between Infrapatellar Fat Pad Volume and Knee Structural Changes in Patients with Knee OA
J. Cai, J. Xu, K. Wang, et al. 1878

The Influence of Weather Conditions on Joint Pain in Older People with OA: Results from the European Project on OSteoArthritis

Erectile Dysfunction Is Common among Patients with Gout
N. Schlesinger, D.C. Radvanski, J.Q. Cheng, J.B. Kostis 1893

Gout and a Subsequent Increased Risk of Erectile Dysfunction in Men Aged 64 and Under: A Nationwide Cohort Study in Taiwan

Alemtuzumab as Remission Induction Therapy in Behçet Disease: A 20-year Experience

Pediatric Rheumatology
Patient-reported Outcomes across Categories of JIA
A.J. Taxter, E.P. Wileyto, E.M. Behrens, P.F. Weiss 1914

Images in Rheumatology
Dysphagia Related to Esophagus Compression by Anterior Cervical Ossification in a Patient with Ankylosing Spondylitis
É. Toussirot, O. Mauvais, S. Aubry 1922

Levamisole-induced Vasculitis in a Cocaine User
E. Hahn, I.I. Bogoch 1924

OMERACT 12 — International Consensus Conference on Outcome Measures in Rheumatology, Budapest, Hungary, May 7-11, 2014

Preconference Meeting
Preconference Introduction — Dialogue on Developing Consensus on Measurement and Presentation of Patient-Important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12

Current State of Reporting of Pain Outcomes in Cochrane Reviews on Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda

Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT

Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain

A Call for Evidence-based Decision Making when Selecting Outcome Measurement Instruments for Summary of Findings Tables in Systematic Reviews: Results from an OMERACT Working Group

Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop

Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee OA Trials: An OMERACT Objective

The OMERACT First-time Participant (“Newbie”) Program: Initial Assessment and Lessons Learned
V.S. Sloan, S. Grosskleg, C. Pohl, G.A. Wells, J.A. Singh 1976

The Spirit of OMERACT: Q Methodology Analysis of Conference Characteristics Valued by Delegates

Correspondence
Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients
S. Monti, S. Breda, V. Grosso, M. Todoerti, C. Montecucco, R. Caporali 1993

Comment M. Genovese 1994

Reply R. Reggia, A. Tincani, F. Franceschini, I. Cavazzana 1995

Letter
14-3-3η in “Seronegative” RA
S.J. Naides, A. Marotta 1995

Meetings in Rheumatology 1996